Susceptibility to hepatitis B virus infection in adults living in Spain
Background A protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all adults with high‐risk behaviours and no seroprotection. However, HBV vaccine c...
Gespeichert in:
| Veröffentlicht in: | Liver international 2023-05, Vol.43 (5), p.1015-1020 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1020 |
|---|---|
| container_issue | 5 |
| container_start_page | 1015 |
| container_title | Liver international |
| container_volume | 43 |
| creator | Soriano, Vicente Aguilera, Antonio Benito, Rafael González‐Díez, Rocío Miró, Elisenda Liendo, Paloma Rodríguez‐Diaz, Juan Carlos Cabezas, Teresa Richart, Alberto Ramos, José Manuel Barea, Luisa Álvarez, Carmen Treviño, Ana Gómez‐Gallego, Félix Corral, Octavio Mendoza, Carmen |
| description | Background
A protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all adults with high‐risk behaviours and no seroprotection. However, HBV vaccine coverage remains globally suboptimal. The advent of new more efficacious trivalent HBV vaccines has renewed the interest in HBV vaccination. At present, the extent of current HBV susceptibility in adults remains unknown in Spain.
Methods
HBV serological markers were assessed on a large and representative sample of adults in Spain, including blood donors and individuals belonging to high‐risk groups. Serum HBsAg, anti‐HBc and anti‐HBs were tested in specimens collected during the last couple of years.
Results
From 13 859 consecutive adults tested at seven cities across the Spanish geography, overall 166 (1.2%) had positive HBsAg. Past HBV infection was recognized in 14% and prior vaccine immunization in 24%. Unexpectedly, 37% of blood donors and 63% of persons belonging to high‐risk groups had no serum HBV markers and therefore were potentially HBV susceptible.
Conclusion
Roughly 60% of adults living in Spain seem to be HBV susceptible. Waning immunity might be more common than expected. Hence, HBV serological testing should be performed at least once in all adults regardless of risk exposures. HBV vaccine full courses or boosters should be administered to all adults lacking serological evidence of HBV protection. |
| doi_str_mv | 10.1111/liv.15548 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2778980587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2778980587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3538-68afa54316424099652eccf33cfa99a69ba941515886e79c0f4b0001752e83d23</originalsourceid><addsrcrecordid>eNp10L1OwzAQB3ALgWgpDLwAisQCQ1p_xIk90gpopUoMBVbLcW1wlSYhdor6NjwLT4YhpQMSXnyyfvr77gA4R3CIwhkVdjNElCbsAPRRkrGYYIIO9zUmPXDi3ApCxDlFx6BHUgY5ZagPpovWKV17m9vC-m3kq-hV19Jbb100jja2aV1kS6OVt1UZqkgu28K7KPxpy5fw8PmxqKUtT8GRkYXTZ7t7AJ7ubh8n03j-cD-b3MxjRShhccqkkTQhKE1wAjlPKdZKGUKUkZzLlOeSJ4giyliqM66gSXIYGs-CY2SJyQBcdbl1U7212nmxtmGCopClrloncJYxziBlWaCXf-iqapsydCdwEBnDKIVBXXdKNZVzjTaibuxaNluBoPherwijip_1BnuxS2zztV7u5e8-Axh14N0Wevt_kpjPnrvIL00Bgw8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2805782160</pqid></control><display><type>article</type><title>Susceptibility to hepatitis B virus infection in adults living in Spain</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Soriano, Vicente ; Aguilera, Antonio ; Benito, Rafael ; González‐Díez, Rocío ; Miró, Elisenda ; Liendo, Paloma ; Rodríguez‐Diaz, Juan Carlos ; Cabezas, Teresa ; Richart, Alberto ; Ramos, José Manuel ; Barea, Luisa ; Álvarez, Carmen ; Treviño, Ana ; Gómez‐Gallego, Félix ; Corral, Octavio ; Mendoza, Carmen</creator><creatorcontrib>Soriano, Vicente ; Aguilera, Antonio ; Benito, Rafael ; González‐Díez, Rocío ; Miró, Elisenda ; Liendo, Paloma ; Rodríguez‐Diaz, Juan Carlos ; Cabezas, Teresa ; Richart, Alberto ; Ramos, José Manuel ; Barea, Luisa ; Álvarez, Carmen ; Treviño, Ana ; Gómez‐Gallego, Félix ; Corral, Octavio ; Mendoza, Carmen</creatorcontrib><description>Background
A protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all adults with high‐risk behaviours and no seroprotection. However, HBV vaccine coverage remains globally suboptimal. The advent of new more efficacious trivalent HBV vaccines has renewed the interest in HBV vaccination. At present, the extent of current HBV susceptibility in adults remains unknown in Spain.
Methods
HBV serological markers were assessed on a large and representative sample of adults in Spain, including blood donors and individuals belonging to high‐risk groups. Serum HBsAg, anti‐HBc and anti‐HBs were tested in specimens collected during the last couple of years.
Results
From 13 859 consecutive adults tested at seven cities across the Spanish geography, overall 166 (1.2%) had positive HBsAg. Past HBV infection was recognized in 14% and prior vaccine immunization in 24%. Unexpectedly, 37% of blood donors and 63% of persons belonging to high‐risk groups had no serum HBV markers and therefore were potentially HBV susceptible.
Conclusion
Roughly 60% of adults living in Spain seem to be HBV susceptible. Waning immunity might be more common than expected. Hence, HBV serological testing should be performed at least once in all adults regardless of risk exposures. HBV vaccine full courses or boosters should be administered to all adults lacking serological evidence of HBV protection.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.15548</identifier><identifier>PMID: 36809581</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Adults ; antibody waning ; Blood ; Blood donors ; diagnosis ; Geography ; Hepatitis ; Hepatitis B ; Hepatitis B - epidemiology ; Hepatitis B - prevention & control ; Hepatitis B Antibodies ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines ; Hepatitis B virus ; Humans ; Immunization ; Infant ; prevention ; public health ; Risk ; Risk groups ; Risk taking ; Serology ; Spain - epidemiology ; vaccine ; Vaccines ; Viruses</subject><ispartof>Liver international, 2023-05, Vol.43 (5), p.1015-1020</ispartof><rights>2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2023 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3538-68afa54316424099652eccf33cfa99a69ba941515886e79c0f4b0001752e83d23</citedby><cites>FETCH-LOGICAL-c3538-68afa54316424099652eccf33cfa99a69ba941515886e79c0f4b0001752e83d23</cites><orcidid>0000-0002-4624-5199</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.15548$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.15548$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36809581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soriano, Vicente</creatorcontrib><creatorcontrib>Aguilera, Antonio</creatorcontrib><creatorcontrib>Benito, Rafael</creatorcontrib><creatorcontrib>González‐Díez, Rocío</creatorcontrib><creatorcontrib>Miró, Elisenda</creatorcontrib><creatorcontrib>Liendo, Paloma</creatorcontrib><creatorcontrib>Rodríguez‐Diaz, Juan Carlos</creatorcontrib><creatorcontrib>Cabezas, Teresa</creatorcontrib><creatorcontrib>Richart, Alberto</creatorcontrib><creatorcontrib>Ramos, José Manuel</creatorcontrib><creatorcontrib>Barea, Luisa</creatorcontrib><creatorcontrib>Álvarez, Carmen</creatorcontrib><creatorcontrib>Treviño, Ana</creatorcontrib><creatorcontrib>Gómez‐Gallego, Félix</creatorcontrib><creatorcontrib>Corral, Octavio</creatorcontrib><creatorcontrib>Mendoza, Carmen</creatorcontrib><title>Susceptibility to hepatitis B virus infection in adults living in Spain</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background
A protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all adults with high‐risk behaviours and no seroprotection. However, HBV vaccine coverage remains globally suboptimal. The advent of new more efficacious trivalent HBV vaccines has renewed the interest in HBV vaccination. At present, the extent of current HBV susceptibility in adults remains unknown in Spain.
Methods
HBV serological markers were assessed on a large and representative sample of adults in Spain, including blood donors and individuals belonging to high‐risk groups. Serum HBsAg, anti‐HBc and anti‐HBs were tested in specimens collected during the last couple of years.
Results
From 13 859 consecutive adults tested at seven cities across the Spanish geography, overall 166 (1.2%) had positive HBsAg. Past HBV infection was recognized in 14% and prior vaccine immunization in 24%. Unexpectedly, 37% of blood donors and 63% of persons belonging to high‐risk groups had no serum HBV markers and therefore were potentially HBV susceptible.
Conclusion
Roughly 60% of adults living in Spain seem to be HBV susceptible. Waning immunity might be more common than expected. Hence, HBV serological testing should be performed at least once in all adults regardless of risk exposures. HBV vaccine full courses or boosters should be administered to all adults lacking serological evidence of HBV protection.</description><subject>Adult</subject><subject>Adults</subject><subject>antibody waning</subject><subject>Blood</subject><subject>Blood donors</subject><subject>diagnosis</subject><subject>Geography</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B - epidemiology</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B Antibodies</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens</subject><subject>Hepatitis B Vaccines</subject><subject>Hepatitis B virus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infant</subject><subject>prevention</subject><subject>public health</subject><subject>Risk</subject><subject>Risk groups</subject><subject>Risk taking</subject><subject>Serology</subject><subject>Spain - epidemiology</subject><subject>vaccine</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L1OwzAQB3ALgWgpDLwAisQCQ1p_xIk90gpopUoMBVbLcW1wlSYhdor6NjwLT4YhpQMSXnyyfvr77gA4R3CIwhkVdjNElCbsAPRRkrGYYIIO9zUmPXDi3ApCxDlFx6BHUgY5ZagPpovWKV17m9vC-m3kq-hV19Jbb100jja2aV1kS6OVt1UZqkgu28K7KPxpy5fw8PmxqKUtT8GRkYXTZ7t7AJ7ubh8n03j-cD-b3MxjRShhccqkkTQhKE1wAjlPKdZKGUKUkZzLlOeSJ4giyliqM66gSXIYGs-CY2SJyQBcdbl1U7212nmxtmGCopClrloncJYxziBlWaCXf-iqapsydCdwEBnDKIVBXXdKNZVzjTaibuxaNluBoPherwijip_1BnuxS2zztV7u5e8-Axh14N0Wevt_kpjPnrvIL00Bgw8</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Soriano, Vicente</creator><creator>Aguilera, Antonio</creator><creator>Benito, Rafael</creator><creator>González‐Díez, Rocío</creator><creator>Miró, Elisenda</creator><creator>Liendo, Paloma</creator><creator>Rodríguez‐Diaz, Juan Carlos</creator><creator>Cabezas, Teresa</creator><creator>Richart, Alberto</creator><creator>Ramos, José Manuel</creator><creator>Barea, Luisa</creator><creator>Álvarez, Carmen</creator><creator>Treviño, Ana</creator><creator>Gómez‐Gallego, Félix</creator><creator>Corral, Octavio</creator><creator>Mendoza, Carmen</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4624-5199</orcidid></search><sort><creationdate>202305</creationdate><title>Susceptibility to hepatitis B virus infection in adults living in Spain</title><author>Soriano, Vicente ; Aguilera, Antonio ; Benito, Rafael ; González‐Díez, Rocío ; Miró, Elisenda ; Liendo, Paloma ; Rodríguez‐Diaz, Juan Carlos ; Cabezas, Teresa ; Richart, Alberto ; Ramos, José Manuel ; Barea, Luisa ; Álvarez, Carmen ; Treviño, Ana ; Gómez‐Gallego, Félix ; Corral, Octavio ; Mendoza, Carmen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3538-68afa54316424099652eccf33cfa99a69ba941515886e79c0f4b0001752e83d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Adults</topic><topic>antibody waning</topic><topic>Blood</topic><topic>Blood donors</topic><topic>diagnosis</topic><topic>Geography</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B - epidemiology</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B Antibodies</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens</topic><topic>Hepatitis B Vaccines</topic><topic>Hepatitis B virus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infant</topic><topic>prevention</topic><topic>public health</topic><topic>Risk</topic><topic>Risk groups</topic><topic>Risk taking</topic><topic>Serology</topic><topic>Spain - epidemiology</topic><topic>vaccine</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soriano, Vicente</creatorcontrib><creatorcontrib>Aguilera, Antonio</creatorcontrib><creatorcontrib>Benito, Rafael</creatorcontrib><creatorcontrib>González‐Díez, Rocío</creatorcontrib><creatorcontrib>Miró, Elisenda</creatorcontrib><creatorcontrib>Liendo, Paloma</creatorcontrib><creatorcontrib>Rodríguez‐Diaz, Juan Carlos</creatorcontrib><creatorcontrib>Cabezas, Teresa</creatorcontrib><creatorcontrib>Richart, Alberto</creatorcontrib><creatorcontrib>Ramos, José Manuel</creatorcontrib><creatorcontrib>Barea, Luisa</creatorcontrib><creatorcontrib>Álvarez, Carmen</creatorcontrib><creatorcontrib>Treviño, Ana</creatorcontrib><creatorcontrib>Gómez‐Gallego, Félix</creatorcontrib><creatorcontrib>Corral, Octavio</creatorcontrib><creatorcontrib>Mendoza, Carmen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soriano, Vicente</au><au>Aguilera, Antonio</au><au>Benito, Rafael</au><au>González‐Díez, Rocío</au><au>Miró, Elisenda</au><au>Liendo, Paloma</au><au>Rodríguez‐Diaz, Juan Carlos</au><au>Cabezas, Teresa</au><au>Richart, Alberto</au><au>Ramos, José Manuel</au><au>Barea, Luisa</au><au>Álvarez, Carmen</au><au>Treviño, Ana</au><au>Gómez‐Gallego, Félix</au><au>Corral, Octavio</au><au>Mendoza, Carmen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Susceptibility to hepatitis B virus infection in adults living in Spain</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2023-05</date><risdate>2023</risdate><volume>43</volume><issue>5</issue><spage>1015</spage><epage>1020</epage><pages>1015-1020</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background
A protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all adults with high‐risk behaviours and no seroprotection. However, HBV vaccine coverage remains globally suboptimal. The advent of new more efficacious trivalent HBV vaccines has renewed the interest in HBV vaccination. At present, the extent of current HBV susceptibility in adults remains unknown in Spain.
Methods
HBV serological markers were assessed on a large and representative sample of adults in Spain, including blood donors and individuals belonging to high‐risk groups. Serum HBsAg, anti‐HBc and anti‐HBs were tested in specimens collected during the last couple of years.
Results
From 13 859 consecutive adults tested at seven cities across the Spanish geography, overall 166 (1.2%) had positive HBsAg. Past HBV infection was recognized in 14% and prior vaccine immunization in 24%. Unexpectedly, 37% of blood donors and 63% of persons belonging to high‐risk groups had no serum HBV markers and therefore were potentially HBV susceptible.
Conclusion
Roughly 60% of adults living in Spain seem to be HBV susceptible. Waning immunity might be more common than expected. Hence, HBV serological testing should be performed at least once in all adults regardless of risk exposures. HBV vaccine full courses or boosters should be administered to all adults lacking serological evidence of HBV protection.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36809581</pmid><doi>10.1111/liv.15548</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-4624-5199</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2023-05, Vol.43 (5), p.1015-1020 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2778980587 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Adults antibody waning Blood Blood donors diagnosis Geography Hepatitis Hepatitis B Hepatitis B - epidemiology Hepatitis B - prevention & control Hepatitis B Antibodies Hepatitis B surface antigen Hepatitis B Surface Antigens Hepatitis B Vaccines Hepatitis B virus Humans Immunization Infant prevention public health Risk Risk groups Risk taking Serology Spain - epidemiology vaccine Vaccines Viruses |
| title | Susceptibility to hepatitis B virus infection in adults living in Spain |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A29%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Susceptibility%20to%20hepatitis%20B%20virus%20infection%20in%20adults%20living%20in%C2%A0Spain&rft.jtitle=Liver%20international&rft.au=Soriano,%20Vicente&rft.date=2023-05&rft.volume=43&rft.issue=5&rft.spage=1015&rft.epage=1020&rft.pages=1015-1020&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.15548&rft_dat=%3Cproquest_cross%3E2778980587%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2805782160&rft_id=info:pmid/36809581&rfr_iscdi=true |